INSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now: the stock is in a sharp downtrend with deteriorating momentum (bearish MAs + MACD worsening), and the fundamental/news flow is dominated by reimbursement/coding uncertainty.", "While the RSI is extremely oversold (bounce potential), the move is being driven by a real catalyst (CMS/MAC coding reversals) rather than a purely technical washout\u2014so dips can keep getting bought and then sold.", "With earnings on 2026-02-11 after hours and the user being unwilling to wait for cleaner confirmation, the risk/reward favors avoiding new longs today."]
["Trend: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling sustained downside pressure.", "Momentum: MACD histogram at -1.388 and negatively expanding \u2192 downside momentum is still accelerating, not stabilizing.", "Mean-reversion setup: RSI_6 = 12.753 (extremely oversold) \u2192 a short-term dead-cat bounce is possible, but it is counter-trend.", "Key levels: Price (~67.9 pre-market) is sitting on/just under S1 = 68.92; if this fails, next support S2 = 61.703. Overhead resistance: Pivot 80.601, then R1 92.283."]
increases odds of a reflex bounce off the ~69 / ~62 support zone.", "Evercore maintained an Outperform and argued FY26 guide may be intact (some support that the business isn\u2019t structurally broken).", "Upcoming earnings (2026-02-
could reset expectations if management provides clear reimbursement/coding pathway and confirms utilization stability."]
["Core catalyst remains negative: CMS/MAC coding and reimbursement \u201cflip-flopping\u201d is creating utilization and physician-incentive headwinds.", "Analyst downgrades clustered around reimbursement clarification/correction (Oppenheimer, Truist, RBC) with major price target cuts\u2014signals diminished near-term confidence.", "News flow includes legal investigation headlines and claims of weak Inspire V launch readiness/demand, adding reputational and execution overhang.", "Downtrend is still strengthening (MACD worsening), meaning technical \u2018oversold\u2019 can persist while price continues to slide."]
["Latest quarter provided: 2025/Q3.", "Revenue: $224.5M, +10.49% YoY (top-line growth still positive).", "Profitability: Net income $9.93M, -46.30% YoY; EPS $0.34, -43.33% YoY (meaningful earnings compression).", "Margins: Gross margin 85.85%, +2.13% YoY (gross margin strong, but opex/other factors appear to be pressuring bottom-line results)."]
["Recent trend: Ratings have turned more cautious with multiple downgrades concentrated in late Jan 2026 tied to reimbursement/coding changes.", "Key changes: RBC downgraded to Sector Perform and slashed PT to $90 (from $175); Oppenheimer downgraded to Perform and removed PT; Truist downgraded to Hold with PT cut to $96.", "Remaining bullish voice: Evercore kept Outperform with PT $125, suggesting guidance may hold despite coding noise.", "Wall Street pros: Large OSA market opportunity and product franchise still viewed as valuable; some belief the guide can hold if reimbursement path normalizes.", "Wall Street cons: Near-term utilization/reimbursement uncertainty, physician disincentives, and Inspire V execution concerns are dominating the narrative and estimates."]
